UCB S. A.

UCB S. A.

UCB S. A.

Overview
Date Founded

1928

Headquarters

C/O UCB INC 1950 LAKE PARK DRIVE SMYRNA GA 30080

Type of Company

Public

Employees (Worldwide)

7,563

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
Commercial Scientific Research
Biotechnology

Company Description

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Website
Executives & Employees

Chief Executive Officer & Chairman of the Executive Committee

Executive Vice President Chief Financial Officer

Chief Operating Officer

Executive Vice President Chief Operating Officer

Executive Vice President General Counsel

Executive Vice President Chief Marketing Officer

Executive Vice President New Medicines Head & Chief Scientific Officer

Chief Medical Officer & Head, Development & Medical Practices

Chief Talent Officer

Executive Vice President Head of the Bone Patient Value Unit

Subscribe now to see full list of current and former executives
Board of Directors

Former Professional at UCB S. A.

Vice Chairman at UCB Pharma SA - Belgium

Former Senior Partner at McKinsey & Co., Inc. (Belgium)

Founder at IDS Capital SA

Chairman & Chief Executive Officer at Hansa Medical AB

Former Chief Executive Officer & Chairman of the Executive Committee at UCB S. A.

Professional at OxStem Ltd.

Head at Nikita SPRL

Former President at Institut Pasteur

Independent Director at UCB S. A.

Subscribe now to see full list of current and former board members
Paths to UCB S. A.
Potential Connections via
Relationship Science
You
UCB S. A.
Owners & Shareholders
Details Hidden

Wellington is an active manager which invests across a range of equity, fixed-income, commodities, alternative and other investment classes following a variety of strategies. Portfolio managers are responsible for both research and investment decisions within their territory, supported by proprietary research which is shared throughout the Wellington group. Their focus is primarily on the UK, Europe, the Middle East and Africa.The firm's proprietary research is the foundation for their investment approach, and is used by specialized teams to invest according to their specific strategies, which combine fundamental research with quantitative valuation techniques. Risk management combines proprietary models and external systems to ensure that portfolios are constructed in line with client risk tolerance.Global industry, regional and macroeconomic experts support both equity and fixed-income investments. Quantitative, technical, style and specialty research teams also contribute to the equity investment processes. Credit, sovereign, quantitative and sector-based analysts support fixed-income investing, working as teams to ensure that bottom-up decisions include relevant top-down factors, and vice versa.Wellington's multi-sector portfolios are regional and multi-currency. They cover the duration spectrum from money market and short bond to intermediate and market duration, core, and core bond plus portfolios. The firm also invests in specific sectors including high yield, corporate, mortgage-backed, emerging markets, and municipal bonds.

Details Hidden

Zadig Asset Management LLP (ZAM) is an independent hedge fund company based in London, UK. The firm was established in 2005 by Laurent Saglio to manage the Zadig Fund, a hedge fund for private individuals and institutions now closed to new investors.Before founding ZAM, Laurent Saglio participated in the creation of Voltaire Asset Management in 1998, which was closed in 2005 after the retirement of Ivan Briery, the firm's other founding partner.

Details Hidden

Hermes Equities is an active, long-term manager which specializes in high-alpha, unconstrained European equity portfolios. They aim to build portfolios of high-conviction, original ideas that will outperform the benchmark without excessive volatility.The firm selects stocks based on a bottom-up approach where they can identify sustained structural change in businesses yet to be recognized by the market. They conduct in-house research, focusing on the key drivers of a business model including capital and product cycles, cash flow, relative value, buyer and supplier power, barriers to entry and secular growth trends.Hermes Equities tests investment ideas against a macroeconomic and thematic framework, seeking emerging fundamental themes that can lead to structural bottlenecks and which could spark a re-pricing of the stocks operating in these areas.

Subscribe now to see full details
Recent Transactions
Details Hidden

UCB S. A. purchases Beryllium Discovery Corp.

Details Hidden

Amphastar Pharmaceuticals, Inc., Amphastar (United Kingdom) Ltd. purchase International Medication Systems (United kingdom) Ltd. from UCB S. A.

Details Hidden

Lannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Subscribe now to see full list of recent transations
Transaction Advisors
Accountant

Advised onUCB S. A. purchases Solutia, Inc. /Resins Additives & Adhesives Businesses from Solutia, Inc.

Investment Advisor

Advised onUCB S. A. purchases UCB Pharma GmbH

Legal Advisor

Advised onUCB S. A. purchases Beryllium Discovery Corp.

Subscribe now to see 19+ more transaction advisors
Associate

Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Legal Advisor

Advised onCytec Industries, Inc. purchases UCB SA /Surface Specialty Business from UCB S. A.

Legal Advisor

Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Subscribe now to see 7+ more transaction advisors
Advisors & Consultants
Subscribe now to see advisors & consultants for over 2.5 million organizations
Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP

Subscribe now to see advisors & consultants for over 2.5 million organizations
Clients

Johnson & Johnson is an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company operates through the following business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. Its baby care franchise includes the JOHNSON'S Baby line of products. The Pharmaceutical segment includes products in the anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines. The Medical Devices segment includes products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. It include products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. Johnson & Johnson was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

Pfizer, Inc. engages in the manufacture of vaccines and injectable biologic medicines. It operates through the Pfizer Innovative Health and Pfizer Essential Health segments. The Pfizer Innovative Health segment focuses on developing and commercializing novel, value-creating medicines, and vaccines for the internal medicine, vaccines, oncology, inflammation and immunology, rare diseases, and consumer healthcare. The Pfizer Essential Health segment comprises of global brands, sterile injectable pharmaceuticals, infusion systems, biosimilars, and Pfizer CentreOne. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Subscribe now to see 15 more clients
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$12.7B
Total Enterprise Value
$12.2B
Earnings Per Share
$2.88
Revenue
$4.18B
Net Profit
$543M
EBITDA
$1.06B
EBITDAMargin
25.47%
Total Debt
$1.6B
Total Equity
$5.48B
Enterprise Value Sales
2.91x
Enterprise Value EBITDAOperating
11.43x
TEVNet Income
22.39x
Debt TEV
0.13x
Three Year Compounded Annual Growth Rate Of Revenue
6.99%
Five Year Compounded Annual Growth Rate Of Revenue
5.18%
Subscribe now to see full financial details
Investments
Details Hidden

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Details Hidden

Lumos Pharma, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Details Hidden

Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada.

Subscribe now to see full investment details
Suppliers
Evotec AG Pharmaceuticals | Hamburg, HA

Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include research fees, milestones and royalties. The EVT Innovate segment focuses on building a longterm partnered pharmaceutical pipeline from its own, internally developed assets and platforms. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

BTS Group AB Management Consulting | Stockholm, AB

BTS Group AB engages in the provision of consultancy solutions and training services. It supports customers with services that monitor the employee from evaluation for selection and development, strategic consensus and strategy implementation through execution, business acumen, leadership development, assessment centers, sales force transformation, and innovation. It operates through the following segments: North America, Europe, Other Markets, and APG. The company was founded by Henrik Ekelund in 1986 and is headquartered in Stockholm, Sweden.

Nektar Therapeutics Pharmaceuticals | San Francisco, CA

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Subscribe now to see 15 more suppliers